GALAPAGOS NV/S (NASDAQ:GLPG) Now Covered by Bank of America

Bank of America initiated coverage on shares of GALAPAGOS NV/S (NASDAQ:GLPG) in a report issued on Monday morning, Benzinga reports. The firm issued a neutral rating and a $199.00 target price on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on GLPG. TheStreet upgraded shares of GALAPAGOS NV/S from a c rating to a b rating in a research report on Tuesday, October 29th. Royal Bank of Canada upped their price target on shares of GALAPAGOS NV/S from $152.00 to $158.00 and gave the company a sector perform rating in a research report on Friday, November 15th. Zacks Investment Research cut shares of GALAPAGOS NV/S from a buy rating to a hold rating in a research report on Thursday, October 31st. Morgan Stanley decreased their price target on shares of GALAPAGOS NV/S to $193.00 and set an overweight rating for the company in a research report on Tuesday, October 29th. Finally, BidaskClub upgraded shares of GALAPAGOS NV/S from a hold rating to a buy rating in a research report on Thursday, October 31st. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of Buy and an average target price of $178.44.

Shares of NASDAQ GLPG opened at $195.39 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.95 and a current ratio of 8.95. GALAPAGOS NV/S has a 52-week low of $85.00 and a 52-week high of $198.54. The firm has a 50 day moving average price of $179.27 and a two-hundred day moving average price of $156.75. The stock has a market cap of $10.73 billion, a P/E ratio of 27.66 and a beta of 1.58.

GALAPAGOS NV/S (NASDAQ:GLPG) last announced its quarterly earnings results on Thursday, October 24th. The biotechnology company reported $8.72 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.41) by $10.13. GALAPAGOS NV/S had a net margin of 32.09% and a return on equity of 25.34%. The firm had revenue of $715.97 million during the quarter, compared to analysts’ expectations of $52.26 million. Analysts predict that GALAPAGOS NV/S will post 7.15 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its position in shares of GALAPAGOS NV/S by 170.7% during the second quarter. Tower Research Capital LLC TRC now owns 249 shares of the biotechnology company’s stock worth $32,000 after buying an additional 157 shares during the period. Royal Bank of Canada increased its position in shares of GALAPAGOS NV/S by 206.1% during the second quarter. Royal Bank of Canada now owns 251 shares of the biotechnology company’s stock worth $32,000 after buying an additional 169 shares during the period. Ladenburg Thalmann Financial Services Inc. acquired a new stake in shares of GALAPAGOS NV/S during the second quarter worth $59,000. Quantamental Technologies LLC acquired a new stake in shares of GALAPAGOS NV/S during the second quarter worth $74,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of GALAPAGOS NV/S during the third quarter worth $109,000. Institutional investors own 15.28% of the company’s stock.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Story: Call Option

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.